Market Size of Anorexiants Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anorexiants Market Analysis
The anorexiants market studied is anticipated to register a CAGR of 3.9% during the forecast period. The major factors attributing to the growth of the market are a rise in the sedentary lifestyle, physical inactivity, and poor dietary habits resultant weight gain. According to the World Health Organization report, in 2017, about 650 million adults and 41 million children aged under 5 years were obese worldwide. Also, the report states that the obesity rate is expected to grow rapidly during the forecast period. Thus, a steep rise in global healthcare expenditure to control other health complications and obesity-related diseases is expected to drive the market.
Anorexiants Industry Segmentation
Anorexiants are therapeutics used to treat obesity by increasing basal metabolic rate. These drugs stimulate hypothalamic and limbic regions that control gastric emptying. Thus, it acts by suppressing the appetite and causing earlier satiety resultant decreasing the intake of the individual. Obesity is identified as the leading preventable cause of preventable death, thus the demand for anorexiants is expected to increase over the forecast period driving the market.
| Route of Administration | |
| Subcutaneous Anorexiants | |
| Oral Anorexiants |
| Distribution Channel | |
| Online Pharmacy | |
| Retail Pharmacy | |
| Hospital Pharmacy |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Anorexiants Market Size Summary
The anorexiants market is poised for steady growth, driven by increasing obesity rates linked to sedentary lifestyles, physical inactivity, and poor dietary habits. The rising prevalence of obesity-related health complications is prompting higher global healthcare expenditures, which in turn is expected to fuel market expansion. Oral anorexiants have been the dominant segment, favored for their non-invasive nature and ease of administration, which does not require skilled healthcare professionals. This preference, coupled with the availability of these products in convenient forms like tablets and capsules, is anticipated to sustain the segment's growth. The market's competitive landscape is characterized by significant investments in research and development, as well as strategic mergers and acquisitions, aimed at enhancing product offerings and market reach.
North America stands out as the primary market for anorexiants, largely due to the high incidence of obesity-related chronic diseases such as diabetes and coronary heart disease. The region's growing obesity rates, exacerbated by unhealthy lifestyle choices, are driving demand for anorexiants. The presence of major industry players and a substantial target population with disposable income further bolster market prospects in this region. Companies like Novo Nordisk Inc., Lannett Co. Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, and Pfizer Inc. are key players in the market, actively engaging in strategic alliances to enhance their global sales. These dynamics underscore the market's potential for continued growth and innovation over the forecast period.
Anorexiants Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles
-
1.2.2 Rise in Awareness and Disposable Income in Developed Economies
-
-
1.3 Market Restraints
-
1.3.1 Highly Cost of Branded Products in Emerging Countries
-
1.3.2 Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death
-
1.3.3 Adoption of Traditional Yoga and Herbal Products
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Route of Administration
-
2.1.1 Subcutaneous Anorexiants
-
2.1.2 Oral Anorexiants
-
-
2.2 Distribution Channel
-
2.2.1 Online Pharmacy
-
2.2.2 Retail Pharmacy
-
2.2.3 Hospital Pharmacy
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Anorexiants Market Size FAQs
What is the current Anorexiants Market size?
The Anorexiants Market is projected to register a CAGR of 3.9% during the forecast period (2024-2029)
Who are the key players in Anorexiants Market?
Novo Nordisk Inc.,, Lannett Co, Inc., F. Hoffmann-La Roche AG, Pfizer Inc. and Currax Pharmaceuticals LLC are the major companies operating in the Anorexiants Market.
